AU
UK
CA
NZ
IND
US
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. announced that the U.S.Food and Drug Administrationhas granted approval for PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s Keytruda (pembrolizumab) or Keytruda QLEX. The therapy is now cleared for perioperative use in adults with muscle-invasive bladder cancer (MIBC) …
Gilead Sciences (NASDAQ:GILD) has completed the acquisition of the TREX1 cancer program from Sprint Bioscience AB. The agreement includes an upfront payment of USD 14 million and future potential milestone payments that could reach as high as USD 400 million.
Veeva Systems (NYSE:VEEV) reported a meaningful revenue increase for its fiscal third quarter ended October 31, 2025, supported by steady demand for its cloud-based solutions tailored to the life sciences sector. Totalrevenuerose 16%year-over-yearto USD 811.2 million, compared with USD 699.2 million in Q3 FY25. …
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) has initiated its Phase 3 CAREFNDR clinical trial evaluating paltusotine in adults with carcinoid syndrome, marking a major step toward expanding the therapeutic reach of its flagship drug. Carcinoid syndrome affects roughly 20 percent of people with neuroendocrine tumors, most …
SynCardia Systems, LLC, a subsidiary of Picard Medical Inc. (NASDAQ:PMI), has reached a defining moment in the advancement of artificial organ technology. The company confirmed the first successful in vivo implantations of its fully implantable Emperor Total Artificial Heart, marking a pivotal milestone in …
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the U.S.Food and Drug Administrationhas approved EYLEA HD (aflibercept injection 8 mg) for adult patients with macular edema following retinal vein occlusion. This approval adds a monthly (every four-week) dosing option across all previously approved indications, including wet …
Amgen (NASDAQ:AMGN) has received full approval from the U.S.Food and Drug Administrationfor IMDELLTRA (tarlatamab-dlle), a targeted therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. This decision upgrades IMDELLTRA’s initial accelerated approval, marking a …
Gilead Sciences, Inc. (Nasdaq:GILD) has taken a crucial step in global HIV prevention with the first deliveries of its twice-yearly injectable PrEP medicine, lenacapavir, to Eswatini and Zambia. These shipments signify an important moment for communities in sub-Saharan Africa, a region that accounts for …
Zymeworks Inc. (Nasdaq:ZYME) has launched a strategic initiative designed to maximize long-term value from its growing roster of licensed biotherapeutics and healthcare assets. This decision follows encouraging developments across key programs, including positive topline data from the pivotal Phase 3 HERIZON-GEA-01 trial for Ziihera …
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) has achieved a major regulatory milestone as the U.S.Food and Drug Administration approvedREDEMPLO (plozasiran) for the treatment of adult patients with familial chylomicronemia syndrome. This marks the company’s first FDA-approved medicine and represents a pivotal step in its evolution from …
Please wait processing your request...